Unique ID issued by UMIN | UMIN000008400 |
---|---|
Receipt number | R000009877 |
Scientific Title | Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer |
Date of disclosure of the study information | 2012/07/11 |
Last modified on | 2016/07/11 19:55:24 |
Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer
Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer
Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer
Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer
Japan |
esophageal cancer
Hematology and clinical oncology | Gastrointestinal surgery |
Malignancy
NO
To determine the efficacy, we conduct phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for esophageal cancer.
Efficacy
Exploratory
Pragmatic
Phase II
objective response rate
duration of response, time to progression, time to treatment failure, overall survival, feasibility
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Docetaxel/cisplatin/5-fluorouracil (docetaxel 60 mg/sm day1, cisplatin 70 mg/sm day1, 5-fluorouracil 600 mg/sm day1-5) given every 4 weeks
Not applicable |
Not applicable |
Male and Female
(1) Pathologically proven advanced esophageal cancer (Stage II to IV).
(2) Written informed consent is obtained from patient.
(3) Major organs are in normal conditions.
Hemoglobin => 8.0g/dL
White blood cell count 3,000 to 12,000/mm3
Neutrophil count => 1,500/mm3
Platelet count => 80,000/mm3
Serum bilirubin <= 2.0 times upper limit of normal
AST, ALT <= 3.0 times upper limit of normal
Serum creatinine <= 1.4 mg/dL
(1) Known hypersensitivity to taxanes, platinum, fluoropyrimidines. Known dihydropyrimidine-dehydrogenase (DPD) deficit.
(2) Pre-existing motor or sensory neurotoxicity of a severity => Grade2
(3) Active infectious diseases.
(4) Symptomatic bleeding tendency, coagulation disorder, or coagulation factor deficiency.
(5) Uncontrollable hypertension, uncontrollable diabetes, unstable angina, or heart failure.
(6) Pre-existing renal insufficiency or proteinuria => 2+.
(7) Clinical or radiographic signs of interstitial pneumonia or pulmonary fibrosis.
(8) Active gastrointestinal bleeding, bowel obstruction.
(9) Patients who are judged inappropriate for the entry into this study by the investigator.
60
1st name | |
Middle name | |
Last name | Yasuhiro Arakawa |
Jikei university school of medicine
Department of oncology and hematology
3-19-18 Nishi-shimbashi Minato-Ku Tokyo Japan
03-3433-1111
yarakawa@jikei.ac.jp
1st name | |
Middle name | |
Last name | Yasuhiro Arakawa |
Jikei university school of medicine
Department of oncology and hematology
3-19-18 Nishi-shimbashi Minato-Ku Tokyo Japan
03-3433-1111
esophagus@jikei.ac.jp
Jikei university school of medicine, department of oncology and hematology, department of gastroenterological surgery
Jikei university school of medicine, department of oncology and hematology
Self funding
NO
2012 | Year | 07 | Month | 11 | Day |
Unpublished
No longer recruiting
2012 | Year | 06 | Month | 25 | Day |
2012 | Year | 07 | Month | 01 | Day |
2012 | Year | 07 | Month | 11 | Day |
2016 | Year | 07 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009877